Breast Cancer Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.The Breast Cancer Clinical Practice Guidelines presented here are the work of the members of the NCCN Breast Cancer Clinical Practice Guidelines Panel. Categories of evidence were assessed and are noted on the algorithms and in the text. Although not explicitly stated at every decision point of the Guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer. The full breast cancer guidelines are not printed in this issue of JNCCN, but can be accessed online at trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewThe American Cancer Society estimated that 184,450 new cases of invasive breast cancer would be diagnosed and 40,930 patients would die of the disease in the United States in 2008.1 In addition, approximately 67,770 women will be diagnosed with carcinoma in situ of the breast during the same...

If the inline PDF is not rendering correctly, you can download the PDF file here.


  • 1

    JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin2008;58:7196.

  • 2

    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:16871717.

  • 3

    GailMHCostantinoJPBryantJ. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999;91:18291846.

  • 4

    DupontWDPageDL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med1985;312:146151.

  • 5

    WhiteJMorrowMMoughanJ. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer2003;97:893904.

  • 6

    WilkinsonNWShahryarinejadAWinstonJS. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg2003;196:3843.

  • 7

    GiordanoSHValeroVBuzdarAUHortobagyiGN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol2002;25:235237.

  • 8

    GiordanoSHBuzdarAUHortobagyiGN. Breast cancer in men. Ann Intern Med2002;137:678687.

  • 9

    GundryKR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park)2005;19:159169; discussion 170 173–154 177.

  • 10

    EssermanL. Integration of imaging in the management of breast cancer. J Clin Oncol2005;23:16011602.

  • 11

    HoussamiNCiattoSMacaskillP. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol2008;26:32483258.

  • 12

    FischerUZachariaeOBaumF. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol2004;14:17251731.

  • 13

    SolinLJOrelSGHwangWT. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol2008;26:386391.

  • 14

    Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April302003. Available at: Accessed October 3 2007.

  • 15

    PuglisiFFolladorAMinisiniAM. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol2005;16:263266.

  • 16

    KumarRChauhanAZhuangH. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat2006;98:267274.

  • 17

    WahlRLSiegelBAColemanREGatsonisCG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol2004;22:277285.

  • 18

    PodoloffDAAdvaniRHAllredC. NCCN Task Force Report: PET/CT scanning in cancer. J Natl Compr Canc Netw2007;5(Suppl 1):S124.

  • 19

    CarrCEConantEFRosenMA. The impact of FDG PET in the staging of breast cancer [abstract]. J Clin Oncol2006:24:18 (Suppl 1):Abstract 530.

  • 20

    KhanQJO’DeaAPDusingR. Integrated FDG-PET for initial staging of breast cancer [abstract]. J Clin Oncol2007;25:18(Suppl 1):Abstract 558.

  • 21

    RosenELEubankWBMankoffDA. FDG PET, PET/CT, and breast cancer imaging. RadiGraphics2007;27:S215229.

  • 22

    WangSSaboorianMHFrenkelE. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol2000;53:374381.

  • 23

    DAKO HercepTest [package insert]. Carpinteria, CA: DAKO Corp; 2004.

  • 24

    Pathway HER2 [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2004.

  • 25

    INFORM HER2/neu gene detection system [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2001.

  • 26

    PathVysion HER2/neu method [package insert]. Downers Grove, IL: Vysis, Inc.; 2001.

  • 27

    SPOT-Light HER2 CISH kit [package insert]. Camarillo, CA: Invitrogen Corp.; 2008.

  • 28

    AndersonSGilkersonEKleinP. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat2002;76:S68:Abstract 235.

  • 29

    PaikSBryantJTan-ChiuE. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst2002;94:852854.

  • 30

    PaikSTan-ChiuEBryantJ. Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat2002;76(Suppl):S31.

  • 31

    PerezEASumanVJDavidsonNE. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol2006;24:30323038.

  • 32

    TubbsRRPettayJDRochePC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol2001;19:27142721.

  • 33

    PressMFSauterGBernsteinL. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res2005;11:65986607.

  • 34

    CarlsonRWMoenchSJHammondMEH. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw2006;4(Suppl 3):S122.

  • 35

    WolffACHammondMESchwartzJN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol2007;25:118147.

  • 36

    CookeTReevesJLaniganAStantonP. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol2001;12(Suppl 1):S2328.

  • 37

    PaikSBryantJParkC. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst1998;90:13611370.

  • 38

    PaikSBryantJTan-ChiuE. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst2000;92:19911998.

  • 39

    PiccartMJDi LeoAHamiltonA. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients?Eur J Cancer2000;36:17551761.

  • 40

    ThorADBerryDABudmanDR. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst1998;90:13461360.

  • 41

    PritchardKIShepherdLEO’MalleyFP. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med2006;354:21032111.

  • 42

    DresslerLGBerryDABroadwaterG. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol2005;23:42874297.

  • 43

    RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005;353:16731684.

  • 44

    Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:16591672.

  • 45

    SlamonDEiermannWRobertN. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.

  • 46

    JoensuuHKellokumpu-LehtinenPLBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006;354:809820.

  • 47

    CobleighMAVogelCLTripathyD. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol1999;17:26392648.

  • 48

    SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;344:783792.

  • 49

    VogelCLCobleighMATripathyD. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol2002;20:719726.

  • 50

    AllredDCHarveyJMBerardoM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol1999;11:155168.

  • 51

    RhodesAJasaniBBarnesDM. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol2000;53:125130.

  • 52

    RudigerTHöflerHKreipeHH. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol2002;26:873882.

  • 53

    ArriagadaRLeMGRochardFContessoG. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol1996;14:15581564.

  • 54

    ClarkeMCollinsRDarbyS. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;366:20872106.

  • 55

    FisherBAndersonSBryantJ. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med2002;347:12331241.

  • 56

    VeronesiUCascinelliNMarianiL. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med2002;347:12271232.

  • 57

    McCormickB. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw2005;3:301307.

  • 58

    PignolJ-POlivottoERakovitchWE. Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol2006;66:S1.

  • 59

    WhelanTMacKenzieRJulianJ. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst2002;94:11431150.

  • 60

    AntoniniNJonesHHoriotJC. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol2007;82:265271.

  • 61

    BartelinkHHoriotJCPoortmansP. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med2001;345:13781387.

  • 62

    JonesHAntoniniNColetteL. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys2007;69(3 Suppl):S23.

  • 63

    FourquetACampanaFZafraniB. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys1989;17:719725.

  • 64

    KomoikeYAkiyamaFIinoY. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer2006;106:3541.

  • 65

    ZhouPGautamSRechtA. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat2007;101:5157.

  • 66

    GolshanMMironANixonAJ. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg2006;192:5862.

  • 67

    KromanNHoltvegHWohlfahrtJ. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer2004;100:688693.

  • 68

    HughesKSSchnaperLABerryD. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med2004;351:971977.

  • 69

    HughesKSSchnaperLABerryD. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.

  • 70

    FylesAWMcCreadyDRManchulLA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med2004;351:963970.

  • 71

    RechtAComeSEHendersonIC. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med1996;334:13561361.

  • 72

    DubeyARechtAComeSE. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys1999;45:877884.

  • 73

    MarkiewiczDASchultzDJHaasJA. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys1996;35:661668.

  • 74

    AbnerALRechtAViciniFA. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys1991;21:331338.

  • 75

    LymanGHGiulianoAESomerfieldMR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol2005;23:77037720.

  • 76

    BassSSLymanGHMcCannCR. Lymphatic mapping and sentinel lymph node biopsy. Breast J1999;5:288295.

  • 77

    CoxCE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol2001;8(9 Suppl):67S70S.

  • 78

    CoxCENguyenKGrayRJ. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?Am Surg2001;67:513519; discussion 519–521.

  • 79

    KragDWeaverDAshikagaT. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med1998;339:941946.

  • 80

    McMastersKMGiulianoAERossMI. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med1998;339:990995.

  • 81

    O’HeaBJHillADEl-ShirbinyAM. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg1998;186:423427.

  • 82

    VeronesiUPaganelliGVialeG. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med2003;349:546553.

  • 83

    KuehnTVoglFDHelmsG. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol2004;30:252259.

  • 84

    ManselREFallowfieldLKissinM. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst2006;98:599609.

  • 85

    DupontECoxCShiversS. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res2001;97:9296.

  • 86

    CoxCESaludCJCantorA. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg2001;193:593600.

  • 87

    AxelssonCKMouridsenHTZedelerK. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer1992;28A:14151418.

  • 88

    KiricutaCITauschJ. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer1992;69:24962501.

  • 89

    FisherBRedmondCFisherER. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med1985;312:674681.

  • 90

    AlkuwariEAugerM. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients. Cancer2008;114:8993.

  • 91

    FisherBBryantJWolmarkN. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol1998;16:26722685.

  • 92

    BearHDAndersonSSmithRE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol2006;24:20192027.

  • 93

    BuzdarAUIbrahimNKFrancisD. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol2005;23:36763685.

  • 94

    SmithIEDowsettMEbbsSR. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol2005;23:51085116.

  • 95

    EllisMJCoopASinghB. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol2001;19:38083816.

  • 96

    HellmanS. Stopping metastases at their source. N Engl J Med1997;337:996997.

  • 97

    OvergaardMJensenMBOvergaardJ. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet1999;353:16411648.

  • 98

    RagazJOlivottoIASpinelliJJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst2005;97:116126.

  • 99

    OvergaardMHansenPSOvergaardJ. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med1997;337:949955.

  • 100

    RechtAEdgeSBSolinLJ. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001;19:15391569.

  • 101

    TheriaultRBuzdarAHortobagyiG. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol1998;17:99a. Abstract 381.

  • 102

    McGuireSEGonzolez-AnguloAMHuangEH. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys2007;68:10041009.

  • 103

    HuangEHTuckerSLStromEA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol2004;22:46914699.

  • 104

    OvergaardMNielsenHMOvergaardJ. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol2007;82:247253.

  • 105

    NielsenHMOvergaardMGrauC. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol2006;24:22682275.

  • 106

    AndersonBOMasettiRSilversteinMJOncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol2005;6:145157.

  • 107

    HuemerGMSchrenkPMoserF. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg2007;120:390398.

  • 108

    MalychaPLGoughIRMargaritoniM. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg2008;32:25702577.

  • 109

    KaurNPetitJY. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol2005;12:539545.

  • 110

    LoprinziCLThomeSD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol2001;19:972979.

  • 111

    RavdinPMSiminoffLADavisGJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol2001;19:980991.

  • 112

    OlivottoIABajdikCDRavdinPM. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol2005;23:27162725.

  • 113

    LoprinziCLRavdinPM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw2003;1:189198.

  • 114

    JeffreySSLonningPEHillnerBE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw2005;3:291300.

  • 115

    SorlieTPerouCMTibshiraniR. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A2001;98:1086910874.

  • 116

    PerouCMJeffreySSvan de RijnM. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A1999;96:92129217.

  • 117

    SorlieTTibshiraniRParkerJ. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A2003;100:84188423.

  • 118

    WangYKlijnJGZhangY. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet2005;365:671679.

  • 119

    van ‘t VeerLJDaiHvan de VijverMJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002;415:530536.

  • 120

    van der VijverMJHeYDvan’t VeerLJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002;347:19992009.

  • 121

    GlasAMFlooreADelahayeLJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics2006;7:278287.

  • 122

    PaikSShakSTangG. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004;351:28172826.

  • 123

    PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol2006;24:37263734.

  • 124

    FanCOhDSWesselsL. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med2006;355:560569.

  • 125

    SwainSMWilsonJWMamounasEP. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst2004;96:516523.

  • 126

    BerryDCirrincioneCHendersonIC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA2006;295:16581667.

  • 127

    AlbainKBarlowWO’MalleyF. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.

  • 128

    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet1998;351:14511467.

  • 129

    BerryDAMussHBThorAD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol2000;18:34713479.

  • 130

    Eppenberger-CastoriSKuengWBenzC. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol2001;19:645656.

  • 131

    KnoopASBentzenSMNielsenMM. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol2001;19:33763384.

  • 132

    MassR. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol2000;27(Suppl):4652; discussion 92–100.

  • 133

    PegramMDPaulettiGSlamonDJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat1998;52:6577.

  • 134

    De LaurentiisMArpinoGMassarelliE. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res2005;11:47414748.

  • 135

    PaikSShakSTangG. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol2005;23:16(Suppl 1): Abstract 510.

  • 136

    ArpinoGGreenSJAllredDC. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res2004;10:56705676.

  • 137

    DowsettMAllredCKnoxJ. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol2008;26:10591065.

  • 138

    CoombesRCKilburnLSSnowdonCF. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet2007;369:559570.

  • 139

    KaufmannMJonatWHilfrichJ. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol2007;25:26642670.

  • 140

    GossPEIngleJNMartinoS. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst2005;97:12621271.

  • 141

    Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:4553.

  • 142

    ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:27472757.

  • 143

    BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:21312139.

  • 144

    HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet2005;365:6062.

  • 145

    DuffySJacksonTLLansdownM. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod2006;21:545553.

  • 146

    FallowfieldLCellaDCuzickJ. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol2004;22:42614271.

  • 147

    EastellRAdamsJEColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol2008;26:10511057.

  • 148

    DowsettMCuzickJHowellAJacksonI. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer2001;85:317324.

  • 149

    BuzdarAUGuastallaJPNabholtzJM. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer2006;107:472480.

  • 150

    MouridsenHKeshaviahACoatesAS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol2007;25:57155722.

  • 151

    BoccardoFRubagottiAPuntoniM. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol2005;23:51385147.

  • 152

    BoccardoFRubagottiAGuglielminiP. Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol2006;17(Suppl 7):vii1014.

  • 153

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

  • 154

    JakeszRJonatWGnantM. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet2005;366:455462.

  • 155

    JonatWGnantMboccardoF. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol2006;7:991996.

  • 156

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

  • 157

    GossPEPEIngleJNPaterJL. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol2008;26:19481955.

  • 158

    WhelanTJGossPEIngleJN. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol2005;23:69316940.

  • 159

    PerezEAJosseRGPritchardKI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol2006;24:36293635.

  • 160

    BravermanASSawhneyHTendlerA. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol2002;21:Abstract 164.

  • 161

    SmithIEDowsettMYapYS. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol2006;24:24442447.

  • 162

    ErbanJKLauJ. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst2006;98:10961097.

  • 163

    Early Breast Cancer Trialists’ Collaborative GroupPolychemotherapy for early breast cancer: an overview of the randomised trials. Lancet1998;352:930942

  • 164

    WoodWCBudmanDRKorzunAH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med1994;330:12531259.

  • 165

    MenardSValagussaPPilottiS. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol2001;19:329335.

  • 166

    MussHBThorADBerryDA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med1994;330:12601266.

  • 167

    BangSMHeoDSLeeKH. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer2000;89:25212526.

  • 168

    FisherBAndersonSTan-ChiuE. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol2001;19:931942.

  • 169

    FisherBBrownAMDimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990;8:14831496.

  • 170

    FisherBAndersonSWickerhamDL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997;15:18581869.

  • 171

    HendersonICBerryDADemetriGD. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol2003;21:976983.

  • 172

    MamounasEPBryantJLemberskyB. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol2005;23:36863696.

  • 173

    CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003;21:14311439.

  • 174

    LevineMNPritchardKIBramwellVH. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol2005;23:51665170.

  • 175

    French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol2001;19:602611.

  • 176

    PiccartMJDi LeoABeauduinM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol2001;19:31033110.

  • 177

    RocheHFumoleauPSpielmannM. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol2006;24:56645671.

  • 178

    MartinMPienkowskiTMackeyJ. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med2005;352:23022313.

  • 179

    SparanoJAWangMMartinoS. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med2008;358:16631671.

  • 180

    SparanoJAWangMMartinoS. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.

  • 181

    JonesSHolmesFO’ShaughnesseyJ. Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.

  • 182

    BursteinHJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med2005;353:16521654.

  • 183

    PerezEARomondEHSumanVJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 512.

  • 184

    Tan-ChiuEYothersGRomondE. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol2005;23:78117819.

  • 185

    PerezEASumanVJDavidsonNE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol2008;26:12311238.

  • 186

    GeyerCEBryantJLRomondMS. Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol2006;24(Suppl 1):Abstract 581.

  • 187

    TelliMLHuntSACarlsonRWGuardinoAE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol2007;25:35253533.

  • 188

    SmithIProcterMGelberRD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet2007:369:2936.

  • 189

    NorrisBChiaSCheangM. Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.

  • 190

    UntchMGelberRDJackischC. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol2008;19:10901096.

  • 191

    HortobagyiGNSingletarySEStromEA. Locally advanced breast cancer. In: HarrisJRLippmanMEMorrowMOsborneCK eds. Diseases of the Breast.3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.

  • 192

    Rosselli Del TurcoMPalliDCariddiA. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA1994;271:15931597.

  • 193

    SmithTJDavidsonNESchapiraDV. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol1999;17:10801082.

  • 194

    The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA1994;271:15871592.

  • 195

    BastRCJrRavdinPHayesDF. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001;19:18651878.

  • 196

    KirovaYMStoppa-LyonnetDSavignoniA. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer2005;41:23042311.

  • 197

    PierceLJLevinAMRebbeckTR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol2006;24:24372443.

  • 198

    MetcalfeKLynchHTGhadirianP. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol2004;22:23282335.

  • 199

    American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol2006;107:14751478.

  • 200

    LoprinziCLKuglerJWSloanJA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet2000;356:20592063.

  • 201

    GarberK. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst2005;97:412413.

  • 202

    JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:3039.

  • 203

    HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:40424057.

  • 204

    OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005;353:487497.

  • 205

    EubankWBMankoffDBhattacharyaM. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol2004;183:479486.

  • 206

    MoonDHMaddahiJSilvermanDH. Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med1998;39:431435.

  • 207

    VernonCCHandJWFieldSB. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys1996;35:731744.

  • 208

    JonesELOlesonJRProsnitzLR. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol2005;23:30793085.

  • 209

    HigginsMJWolffAC. Therapeutic options in the management of metastatic breast cancer. Oncology2008;22:614623; discussion 623 627–629.

  • 210

    TheriaultRLBiermannJSBrownE. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw2006;(4 Suppl 2):S120.

  • 211

    ContePFLatreilleJMauriacL. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol.1996;14:25522559.

  • 212

    HortobagyiGNTheriaultRLLiptonA. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol1998;16:20382044.

  • 213

    TheriaultRLLiptonAHortobagyiGN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol1999;17:846854.

  • 214

    BerensonJRRosenLSHowellA. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer2001;91:11911200.

  • 215

    AliSMEstevaFJHortobagyiG. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol2001;19:34343437.

  • 216

    TheriaultRL. The role of bisphosphonates in breast cancer. J Natl Compr Canc Netw2003;1:232241.

  • 217

    RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377387.

  • 218

    RosenLSGordonDHDuganWJr. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100:3643.

  • 219

    LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:10821090.

  • 220

    HortobagyiGNTheriaultRLPorterL. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med1996;335:17851971.

  • 221

    DielIJBodyJJLichinitserMR. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer2004;40:17041712.

  • 222

    McLachlanSACameronDMurrayR. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig2006;26:4348.

  • 223

    PecherstorferMRivkinSBodyJJ. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig2006;26:315322.

  • 224

    LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:10821090.

  • 225

    RosenLSGordonDKaminskiM. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer2003;98:17351744.

  • 226

    WilkinsonGSKuoYFFreemanJLGoodwinJS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst2007;99:10161024.

  • 227

    WooSBHellsteinJWKalmarJR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med2006;144:753761.

  • 228

    BuzdarADoumaJDavidsonN. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol2001;19:33573366.

  • 229

    BuzdarAUJonatWHowellA. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer1998;83:11421152.

  • 230

    BonneterreJThurlimannBRobertsonJF. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol2000;18:37483757.

  • 231

    NabholtzJMBuzdarAPollakM. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol2000;18:37583767.

  • 232

    VergoteIBonneterreJThurlimannB. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer2000;36(Suppl 4):S8485.

  • 233

    ParidaensRTherassePDirixL. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol2004;22:14S (Suppl 1):Abstract 515.

  • 234

    KlijnJGBlameyRWBoccardoF. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol2001;19:343353.

  • 235

    OsborneCKPippenJJonesSE. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol2002;20:33863395.

  • 236

    HowellARobertsonJFQuaresma AlbanoJ. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol2002;20:33963403.

  • 237

    RobertsonJFOsborneCKHowellA. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer2003;98:229238.

  • 238

    IngleJNSumanVJRowlandKM. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol2006;24:10521056.

  • 239

    ChiaSGradisharWMauriacL. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol2008;26:16641670.

  • 240

    LonningPEBajettaEMurrayR. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol2000;18:22342244.

  • 241

    DombernowskyPSmithIFalksonG. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol1998;16:453461.

  • 242

    BuzdarAJonatWHowellA. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol1996;14:20002011.

  • 243

    CarrickSParkerSWilckenN. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev2005;2:CD003372.

  • 244

    SledgeGWNeubergDBernardoP. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol2003;21:588592.

  • 245

    O’ShaughnessyJMilesDVukeljaS. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol2002;20:28122823.

  • 246

    AlbainKNagSCalderillo-RuizJ. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol2004;22:14s(Suppl 1):Abstract 510.

  • 247

    MussHBCaseLDRichardsFII. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med1991:325;13421348.

  • 248

    FalksonGGelmanRPandyaK. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol1998;16:16691676.

  • 249

    MillerKDWangMGralowJ. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med2007;357:26662676.

  • 250

    RocheHYelleLCognettiF. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol2007;25:34153420.

  • 251

    ThomasETaberneroJFornierM. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol2007;25:33993406.

  • 252

    PerezEALerzoGPivotX. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol2007;25:34073414.

  • 253

    ThomasESGomezHLLiRK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol2007;25:52105217.

  • 254

    SeidmanADBerryDCirrincioneC. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol2008;26:16421649.

  • 255

    RochePCSumanVJJenkinsRB. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst2002;94:855857.

  • 256

    RobertNLeyland-JonesBAsmarK. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol2006;24:27862792.

  • 257

    BursteinHJKeshaviahABaronAD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer2007;110:965972.

  • 258

    YamamotoDIwaseSKitamuraK. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol2008;61:509514.

  • 259

    SchallerGBangemannNWeberJ. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol2005;23:18(Suppl 1):Abstract 717.

  • 260

    SeidmanAHudisCPierriMK. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol2002;20:12151221.

  • 261

    BartschRWenzelCAltorjaiG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol2007;25:38533858.

  • 262

    Von MinckwitzGVogelPSchmidtM. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—interim report [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4056.

  • 263

    Von MinckwitzGZielinskiCMaarteenseE. Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1025.

  • 264

    GeyerCEForsterJLindquistD. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med2006;355:27332743.

  • 265

    O’ShaughnessyJBlackwellKLBursteinH. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1015.

  • 266

    HortobagyiGN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer1994;74:416423.

  • 267

    KhanSAStewartAKMorrowM. Does aggressive local therapy improve survival in metastatic breast cancer?Surgery2002;132:620627.

  • 268

    BabieraGVRaoRFengL. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol2006;13:776782.

  • 269

    RapitiEVerkooijenHMVlastosG. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol2006;24:27432749.

  • 270

    RaoRFengLKuererHM. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol2008;15:16961702.

  • 271

    MorrowMGoldsteinLJ. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?J Clin Oncol2006;24:26942696.

  • 272

    OlsonJAMarcomPK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg2008;247:739740.

  • 273

    JaiyesimiIABuzdarAUHortobagyiG. Inflammatory breast cancer: a review. J Clin Oncol1992;10:10141024.

  • 274

    DawoodSCristofanilliM. What progress have we made in managing inflammatory breast cancer?Oncology2007;21:673687.

  • 275

    GreeneFLPageDLFlemingID. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.

  • 276

    HaagensenCD. Inflammatory carcinoma. In: HaagensenCD ed. Diseases of the Breast. Philadelphia, PA: WB Saunders1956: pp 488498.

  • 277

    ParadisoATommasiSBrandiM. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer1989;1:19221927.

  • 278

    TurpinEBiècheIBertheauP. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene2002;21:75937597.

  • 279

    CristofanilliMValeroVBuzdarAU. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer2007;110.14361444.

  • 280

    PanadesMOlivottoIASpeersCH. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol23:19411950.

  • 281

    MerajverSDWeberBLCodyR. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience. J Clin Oncol1997;15:28732881.

  • 282

    HanceKWAndersonWFDevesaSS. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Instit2005;97:966975.

  • 283

    NguyenDMSamKTsimelzonA. Molecular heterogeneity of inflammatory breast cancer; a hyperproliferative phenotype. Clin Cancer Res2006;12:50475054.

  • 284

    BleicherRJMorrowM. What progress have we made in managing inflammatory breast cancer? The Dawood/Cristofanilli article reviewed. Oncology2007;21:679680.

  • 285

    FlemingRYAsmarLBuzdarAU. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast cancer. Ann Surg Oncol1997;4:452461.

  • 286

    UenoNTBuzdarAUSingletarySE. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol1997;40:321324.

  • 287

    TherassePMauriacLWelnicka-JaskiewiczM. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol2003;21:843850.

  • 288

    CristofanilliMGonzalez-AnguloAMBuzdarAU. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer2004;4:415419.

  • 289

    KimTLauJErbanJ. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer2006;7:386395.

  • 290

    KellMRMorrowM. Surgical aspects of inflammatory breast cancer. Breast Dis2005–2006;22:6773.

  • 291

    BlanchardDKShettyPBHilsenbeckSGElledgeRM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg2008;247:732738.

  • 292

    VaradarajanREdgeSBYuJ. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology2006;71:456459.

  • 293

    OlsonJAMorrisEAVan ZeeKJ. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol2000;7:411415.

Article Information


Google Scholar

Related Articles


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 114 114 67
PDF Downloads 44 44 38
EPUB Downloads 0 0 0